论文部分内容阅读
目的 研究微导管在肝癌介入治疗中的应用价值。方法 经股动脉穿刺对 3 0例肝癌患者共行 87次经微导管肝动脉化疗栓塞 (TACE)。其中肝动脉过分迂曲者 9例 ,肿瘤较小局限于一肝段者 8例 ,肝癌并肝动 -肝静脉瘘 (AVS)和肝动-门静脉瘘 (APVS)者 6例 ,乏血供肿瘤 4例 ,肝门部肿瘤 3例。结果 术后 1周检查示肿瘤内碘油聚集良好 ,正常肝组织未见碘油沉积。 1月后复查 ,肿瘤缩小 75 % 12例、5 0 % 9例、2 5 % 9例 ,1年生存率 67% (2 0 /3 0 ) ,2年生存率 5 3 % (16/3 0 )。结论 微导管在肝癌的介入治疗中有较多的优越性 ,特别是可以为肝段性栓塞和超选插管困难者提供技术支持。
Objective To study the value of microcatheter in the interventional therapy of liver cancer. Methods Totally 87 catheterized transcatheter arterial chemoembolization (TACE) were performed in 30 patients with hepatocellular carcinoma via femoral artery puncture. Among them, there were 9 cases with excessive tortuous hepatic artery, 8 cases with small tumor confined to a hepatic segment, 6 cases with liver cancer with hepatic artery-hepatic venous fistula (AVS) and hepatic arteriovenous fistula (APVS) Cases, hilar tumors in 3 cases. Results 1 week after surgery showed that the accumulation of iodized oil in the tumor well, no normal liver lipiodol deposition. After 1 month, the tumor size decreased 75% in 12 cases, 50% in 9 cases, 25% in 9 cases, 1-year survival rate was 67% (20/30), and 2-year survival rate was 53% ). Conclusion Microcatheter has many advantages in the interventional treatment of liver cancer, especially it can provide technical support for the patients with hepatic segmental embolism and extra-selective intubation.